Background: Morphine-6-glucuronide (M6G) is a metabolite of morphine with potent analgesic properties. The influence of M6G on respiratory and antinociceptive responses was investigated in mice lacking the micro -opioid receptor (MOR) and compared with morphine.

Methods: Experiments were performed in mice lacking exon 2 of the MOR (n=18) and their wild type (WT) littermates (n=20). The influence of M6G and morphine on respiration was measured using whole body plethysmography during three elevations of inspired carbon dioxide. Antinociception was assessed using tail flick and hotplate tests.

Results: In WT but not null mutant mice, a dose-dependent depression of the slope of the ventilatory carbon dioxide response was observed after M6G and morphine. Similarly, both opioids were devoid of antinociceptive effects in null mutant mice, but showed potent dose-dependent analgesia in WT animals. Potency differences between M6G and morphine in WT mice were of the same order of magnitude for analgesia and respiration.

Conclusions: The data indicate that the desired (antinociceptive) and undesired (respiratory depression) effects of M6G and morphine are linked to the same gene product; that is the MOR. Other opioid- and non-opioid-receptor systems may play a minor role in the actions of M6Gs and morphine. The clinical implications of our findings are that any agent acting at the MOR will invariably cause (potent) analgesia in combination with (variable) respiratory depression.

Download full-text PDF

Source
http://dx.doi.org/10.1093/bja/aeg279DOI Listing

Publication Analysis

Top Keywords

m6g morphine
16
antinociceptive responses
8
wild type
8
influence m6g
8
mice lacking
8
carbon dioxide
8
null mutant
8
mutant mice
8
respiratory depression
8
morphine
7

Similar Publications

Pharmacokinetics and thermal anti-nociceptive effects of oral morphine in horses.

Front Vet Sci

September 2024

Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.

Article Synopsis
  • Morphine is effective for pain relief in horses, but intravenous (IV) use can cause unwanted side effects like neuroexcitation and gastrointestinal issues.
  • Oral administration of morphine yields similar pain-relief potential through the metabolite M6G without the negative effects of IV administration.
  • The study found that oral morphine doses provided effective pain relief comparable to IV morphine while causing less excitation and gastrointestinal disturbances, indicating the need for further research.
View Article and Find Full Text PDF

Morphine is a widely used opioid for the treatment of pain. Differences in drug transporter expression and activity may contribute to variability in morphine pharmacokinetics and response. Using appropriate mouse models, we investigated the impact of the efflux transporters ABCB1 and ABCG2 and the OATP uptake transporters on the pharmacokinetics of morphine, morphine-3-glucuronide (M3G), and M6G.

View Article and Find Full Text PDF

Background And Purpose: Morphine is important for treatment of acute and chronic pain. However, there is high interpatient variability and often inadequate pain relief and adverse effects. To better understand variability in the dose-effect relationships of morphine, we investigated the effects of its non-linear blood-brain barrier (BBB) transport on μ-receptor occupancy in different CNS locations, in conjunction with its main metabolites that bind to the same receptor.

View Article and Find Full Text PDF

Background: High-alert medication (HAM) is more predictable to cause significant harm to the patient, even when used as intended. The damage related to the HAM lead not only suffering to the patient, but also raise the additional costs associated with care.

Objective: Evaluate the incidence of drug-related adverse events related to the use of high-alert medications.

View Article and Find Full Text PDF

Morphine and morphine-6-glucuronide (M6G) produce central nervous system (CNS) effects by activating mu-opioid receptors, while naloxone is used mainly for the reversal of opioid overdose, specifically for the fatal complication of respiratory depression, but also for alleviating opioid-induced side effects. In this study we developed a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model to simultaneously predict pharmacokinetics and CNS effects (miosis, respiratory depression and analgesia) of morphine as well as antagonistic effects of naloxone against morphine. The pharmacokinetic and pharmacodynamic parameters were obtained from in vitro data, in silico, or animals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!